Bayer’s Recovery Narrative Tempered by Valuation Gap as Shareholders Reckon with Decade-Old Defense Legacy
Bayer celebrates recent positive news for its life‑science business but reminds investors that the share price remains well below its previous record levels, highlighting the impact of a decade‑old poison‑pill and offering guidance on interpreting the stock’s performance.